EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Integrated Analysis of Single‐Cell and Bulk RNA‐Seq Reveals ZFP36 as a Novel Endothelial Biomarker for Precision Oncology in Bladder Cancer

Yicheng Lu, Ruiqi Sun, Bin Qin, Yangbo Guan

Human Mutation · 2026-01 · 2026 (1)

DOI: 10.1155/humu/2093161 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Mutation, online erschienen am 10.08.2026. Verfasst von Yicheng Lu und 3 weiteren Autor:innen. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Bladder urothelial carcinoma (BLCA) is characterized by extensive genomic instability and complex tumor microenvironmental remodeling. Although endothelial cell‐related genes have been implicated in cancer progression, their mutation spectrum, copy number alterations, and mutation‐associated biological consequences in BLCA remain insufficiently defined.

Methods

We integrated single‐cell RNA sequencing, bulk transcriptomic profiles, somatic mutation data, copy number variation (CNV) information, and clinical datasets from TCGA‐BLCA and multiple GEO cohorts. Endothelial cell‐related genes were identified from single‐cell analysis and intersected with BLCA‐associated differentially expressed genes. Somatic mutation patterns, single‐nucleotide variant classes, CNV distributions, and survival associations were systematically evaluated. ZFP36 alteration status was further used to stratify patients into altered and unaltered groups, followed by differential expression, GO, and KEGG enrichment analyses. Prognostic relevance and immunotherapy response were assessed using independent cohorts, and functional effects were examined in BLCA cell lines.

Results

Thirteen endothelial‐related genes showed detectable somatic mutations or CNVs in BLCA. Mutation analysis revealed recurrent alterations in DUSP1, CXCR4, JUN, DNAJB4, HSPA1A, CREM, RGS2, and ZFP36, with missense mutations as the predominant variant type and C > T transition as the major SNV class. CNV analysis demonstrated both heterozygous and homozygous amplification/deletion events across these genes. ZFP36 alteration occurred in approximately 6% of BLCA samples and was mainly represented by amplification. Compared with the ZFP36‐unaltered group, the altered group exhibited distinct transcriptional changes enriched in mismatch repair, leukocyte transendothelial migration, Fc gamma R‐mediated phagocytosis, immune effector processes, epithelial differentiation, and T‐cell activation. Clinically, ZFP36 expression was associated with prognosis, endothelial infiltration, and immune checkpoint blockade response.

Conclusion

This study defines the mutation and CNV landscape of endothelial‐related genes in BLCA and identifies ZFP36 alteration as a mutation‐associated molecular feature linked to immune and endothelial regulatory pathways. These findings provide mutation‐centered evidence supporting ZFP36 as a candidate biomarker for BLCA stratification.

Zitieren

APA

Lu, Y., Sun, R., Qin, B., & Guan, Y. (2026). Integrated Analysis of Single‐Cell and Bulk RNA‐Seq Reveals ZFP36 as a Novel Endothelial Biomarker for Precision Oncology in Bladder Cancer. Human Mutation, 2026(1). https://doi.org/10.1155/humu/2093161

Vancouver

Lu Y, Sun R, Qin B, Guan Y. Integrated Analysis of Single‐Cell and Bulk RNA‐Seq Reveals ZFP36 as a Novel Endothelial Biomarker for Precision Oncology in Bladder Cancer. Human Mutation. 2026;2026(1). doi:10.1155/humu/2093161

BibTeX
@article{Lu2026,
  author = {Lu, Yicheng and Sun, Ruiqi and Qin, Bin and Guan, Yangbo},
  title = {Integrated Analysis of Single‐Cell and Bulk RNA‐Seq Reveals ZFP36 as a Novel Endothelial Biomarker for Precision Oncology in Bladder Cancer},
  journal = {Human Mutation},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/humu/2093161}
}
Kostenlos starten →